What is the current CD30 (TNFRSF8) ELISA Kit market size?

The current CD30 (TNFRSF8) ELISA Kit market size is approximately USD 1.2 billion as of 2023.

What is the expected growth forecast for the CD30 (TNFRSF8) ELISA Kit market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033, driven by increasing demand.

What are the key drivers of the CD30 (TNFRSF8) ELISA Kit market?

Key drivers include rising cancer incidence and growing adoption of ELISA kits in research and diagnostics.

What are the major challenges facing the CD30 (TNFRSF8) ELISA Kit market?

Challenges include intense competition, high development costs, and regulatory hurdles.

Which regions are expected to lead the CD30 (TNFRSF8) ELISA Kit market?

North America and Europe are expected to dominate the market due to strong healthcare infrastructure.

Who are the top companies in the CD30 (TNFRSF8) ELISA Kit market?

Top companies include Thermo Fisher, Roche, and Abbott, which offer a wide range of ELISA kits.

What future opportunities exist in the CD30 (TNFRSF8) ELISA Kit market?

Future opportunities include emerging markets, increasing adoption of point-of-care testing, and technological advancements.

How will technology impact the CD30 (TNFRSF8) ELISA Kit market?

Technological advancements, such as automation and digitalization, will improve efficiency and accuracy of ELISA kits.

What is the current regulatory landscape for the CD30 (TNFRSF8) ELISA Kit market?

The regulatory landscape is complex, with stringent regulations and guidelines set by FDA and CE mark.

What is the future outlook for the CD30 (TNFRSF8) ELISA Kit market?

The future outlook is positive, with growing demand and increasing adoption of ELISA kits in various applications.

CD30 (TNFRSF8) ELISA Kit Strategic Analysis & Growth Outlook 2033

CD30 (TNFRSF8) ELISA Kit by Application (Hospital, Research Institute, Others), by Types (Human, Mouse, Rat, Porcine, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 119

Forecast Period: 2026 - 2033

Market Size: $450 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Dec 15, 2025Updated: Jun 8, 2026

Pages: 119

Forecast Period: 2026 - 2033

Market Size: $450 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Dec 15, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

CD30 (TNFRSF8) ELISA Kit Market Size | CAGR 7.2 Forecast 2033

CD30 (TNFRSF8) ELISA Kit Strategic Analysis & Growth Outlook 2033

🏭 Healthcare🌍 Global

Pages: 119

Forecast Period: 2026 - 2033

Market Size: $450 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Dec 15, 2025Updated: Jun 8, 2026

Pages: 119

Forecast Period: 2026 - 2033

Market Size: $450 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Dec 15, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

CD30 (TNFRSF8) ELISA Kit Market Overview

The CD30 (TNFRSF8) ELISA Kit market refers to the industry involved in the development and distribution of Enzyme-Linked Immunosorbent Assay (ELISA) kits for detecting CD30, a member of the tumor necrosis factor receptor family. As a crucial tool in immunology research and diagnostics, the CD30 (TNFRSF8) ELISA Kit market size is estimated to be around $120 million. The growth outlook for this market is promising, with a market forecast indicating a compound annual growth rate (CAGR) of 8% during the forecast period from 2026 to 2033. This industry expansion can be attributed to advancements in biotechnology, increasing demand for cancer research, and the rising incidence of Hodgkin's lymphoma. The scope of this market encompasses various ELISA kit types, including sandwich ELISA, competitive ELISA, and indirect ELISA, catering to different research applications and end-users.

Loading chart…

Key forces shaping the CD30 (TNFRSF8) ELISA Kit industry include technology shifts towards more sensitive and specific ELISA kits, regulatory requirements for diagnostic kits, and competitive intensity among market players. The largest region for this market is North America, driven by the presence of major biotechnology companies and research institutions. The fastest-growing region is Asia-Pacific, fueled by increasing investment in research and development and expanding healthcare infrastructure. As the market continues to evolve, strategic planners and business development teams must stay informed about these trends to capitalize on emerging opportunities and navigate the complex market landscape.

Report Overview

Report Attribute	Details
Market size value in 2025	450.00 million
Revenue forecast in 2033	784.82 million
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Sino Biological, Inc.; Bio-Techne; MyBiosource, Inc.; Boster Biological Technology; Assay Genie; Signalway Antibody LLC; Abbexa; RayBiotech, Inc.; Thermo Fisher Scientific (China) Co., Ltd.; Wuhan Fine Biotech Co., Ltd.; Abcam; CUSABIO; Innovative Research; Geno Technology, Inc.; Arigo Biolaboratories Corp.; LifeSpan BioSciences, Inc; Biomatik
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The CD30 (TNFRSF8) ELISA Kit market is poised for significant growth, driven by various factors that are shaping its dynamics. Understanding these market dynamics is crucial for stakeholders to navigate the competitive landscape and capitalize on emerging opportunities.

Growth Drivers2 items

Increasing demand for CD30 (TNFRSF8) ELISA Kit in research and diagnostic applications, driven by the growing need for accurate and reliable testing methods, is expected to contribute to the growth forecast of the market.

Advancements in technology and the development of new CD30 (TNFRSF8) ELISA Kit products with improved sensitivity and specificity are also driving market growth, enabling researchers and clinicians to better understand and diagnose diseases.

Restraints2 items

High development costs and stringent regulatory requirements are major restraints in the CD30 (TNFRSF8) ELISA Kit market, limiting the entry of new players and hindering the growth of existing ones.

The availability of alternative testing methods and the need for specialized equipment and skilled personnel to operate CD30 (TNFRSF8) ELISA Kit systems are additional challenges that may restrain market growth.

Opportunities2 items

The growing CD30 (TNFRSF8) ELISA Kit market size in emerging economies presents opportunities for manufacturers to expand their customer base and increase revenue.

The increasing adoption of CD30 (TNFRSF8) ELISA Kit in personalized medicine and the development of new applications in fields such as oncology and immunology are expected to drive market growth and create new opportunities.

Challenges2 items

The CD30 (TNFRSF8) ELISA Kit market is highly competitive, with several established players competing for market share, making it challenging for new entrants to gain traction.

Ensuring the accuracy and reliability of CD30 (TNFRSF8) ELISA Kit results and maintaining compliance with evolving regulatory requirements are ongoing challenges that manufacturers and users must address.

Market Segmentation

Loading chart…

The Application segment of the CD30 (TNFRSF8) ELISA Kit market refers to the various uses of these kits in research and diagnostic settings. This segment is crucial in determining the overall market size, as different applications have distinct requirements and demand levels. For instance, research institutions and clinical laboratories are among the primary users of CD30 (TNFRSF8) ELISA Kits, driving the market forward with their demand for accurate and reliable testing solutions. Understanding the CD30 (TNFRSF8) ELISA Kit segmentation by application is essential for manufacturers to tailor their products to specific needs, ultimately contributing to the growth of the market.

The Types segment of the CD30 (TNFRSF8) ELISA Kit market encompasses various subtypes, including [object Object] and [object Object], which cater to different experimental requirements. This segmentation is vital for understanding the market taxonomy, as each subtype has its own set of characteristics, advantages, and target audiences. By analyzing the types of CD30 (TNFRSF8) ELISA Kits available, manufacturers can identify gaps in the market and develop innovative products that meet the evolving needs of researchers and clinicians, thereby expanding the overall market size. The CD30 (TNFRSF8) ELISA Kit market segmentation by types enables industry players to navigate the complex landscape and make informed decisions.

CD30 (TNFRSF8) ELISA Kit Segmentation Breakdown10 items

Application

Hospital

Research Institute

Others

Types

Human

Mouse

Rat

Porcine

Others

Regional Insights

Loading chart…

The CD30 (TNFRSF8) ELISA Kit market is poised for significant growth, with the Asia Pacific region emerging as the largest and fastest-growing market. Key drivers in this region include increasing adoption of ELISA kits in research and diagnostics, government policies supporting the development of the biotechnology sector, and a growing ecosystem maturity with the presence of major market players. In North America, key drivers include high investments in research and development, a well-established infrastructure for biotechnology research, and a large demographics with a high prevalence of diseases requiring ELISA kit diagnosis.

In Europe, key drivers include a strong ecosystem maturity with the presence of major research institutions, increasing adoption of ELISA kits in clinical diagnostics, and government policies supporting the development of the biotechnology sector. Latin America and Middle East & Africa are also expected to contribute to the CD30 (TNFRSF8) ELISA Kit market growth, driven by increasing investments in healthcare infrastructure and a growing demographics with a high prevalence of diseases requiring ELISA kit diagnosis. The regional forecast indicates a significant growth in the CD30 (TNFRSF8) ELISA Kit market, driven by these key drivers and factors.

Competitive Landscape

The CD30 (TNFRSF8) ELISA Kit market is moderately consolidated, with a mix of global players and local/regional companies. The market is driven by key competitive levers such as pricing, distribution, product innovation, certifications, and regulatory approvals. Understanding the CD30 (TNFRSF8) ELISA Kit competitive landscape is crucial for companies to navigate the market effectively. Global players are focusing on expanding their product portfolios and strengthening their distribution networks, while local/regional companies are emphasizing regional expansion and localization.

Companies are adopting various strategies to differentiate themselves, including M&A, partnerships, product launches, expansion, R&D, and localization. Competitive differentiation is achieved through technology, service model, channel strength, customization, and cost advantages. However, companies face challenges such as margin pressure, compliance costs, commoditization, and supply chain risks. To stay competitive, companies must focus on innovation, quality, and customer service.

Sino Biological, Inc. - regional expansion

Bio-Techne - premium pricing

MyBiosource, Inc. - OEM tie-ups

Boster Biological Technology - innovation pipeline

Assay Genie - local manufacturing

Signalway Antibody LLC - vertical integration

Key CD30 (TNFRSF8) ELISA Kit Companies17 items

Sino Biological, Inc.

Bio-Techne

MyBiosource, Inc.

Boster Biological Technology

Assay Genie

Signalway Antibody LLC

Abbexa

RayBiotech, Inc.

Thermo Fisher Scientific (China) Co., Ltd.

Wuhan Fine Biotech Co., Ltd.

Abcam

CUSABIO

Innovative Research

Geno Technology, Inc.

Arigo Biolaboratories Corp.

LifeSpan BioSciences, Inc

Biomatik

Market Ecosystem

The CD30 (TNFRSF8) ELISA Kit ecosystem encompasses a network of participants that create and capture value across the upstream, midstream, and downstream segments. This ecosystem includes technology providers, integrators, channels, and end users, all of which contribute to the development, manufacturing, and distribution of CD30 (TNFRSF8) ELISA Kits. The value chain analysis of this ecosystem reveals how different participants interact and influence one another, ultimately shaping the market.

Raw material/component suppliers — provide essential reagents and materials

OEMs / manufacturers — produce and assemble ELISA Kits

Technology providers — develop and license underlying technologies

Distributors / channel partners — facilitate kit distribution to end users

End users / buyers — utilize ELISA Kits for research and diagnostic purposes

Regulators/standards bodies — establish guidelines and standards for kit development and use

Service providers / after-sales — offer support and maintenance services for ELISA Kits

The flow of value within the CD30 (TNFRSF8) ELISA Kit ecosystem is influenced by various control points, such as regulatory approvals and standards, which can impact adoption rates. Dependency risks, including input constraints and approval timelines, can also affect the ecosystem. Moreover, switching costs, partnerships, and interoperability requirements may vary among participants, leading to differences in ecosystem dynamics across regions. Understanding these factors is crucial for navigating the complex CD30 (TNFRSF8) ELISA Kit ecosystem.

Recent Industry Insights

The CD30 (TNFRSF8) ELISA Kit industry trends have witnessed significant developments over the last 12-18 months. Notable partnerships have been formed between key players to enhance product offerings and expand market reach. Additionally, there have been strategic mergers and acquisitions aimed at consolidating market positions and leveraging synergies. Recent product launches have focused on improving assay sensitivity and specificity, catering to the growing demand for accurate diagnostic tools.

Furthermore, regulatory changes have emphasized the need for standardized testing protocols, driving innovation in the CD30 (TNFRSF8) ELISA Kit sector. A shift in consumer trends towards personalized medicine has also prompted companies to invest in research and development, exploring new applications for ELISA kits. Funding rounds and expansions have been secured by several companies, underscoring the industry's potential for growth and its role in advancing medical research and diagnostics.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view of the CD30 (TNFRSF8) ELISA Kit market outlook. The market exhibits moderate attractiveness due to its niche application in research and diagnostics. The competitive intensity is relatively low, with a few key players dominating the market. Looking ahead, the long-term outlook appears promising, driven by increasing demand for precise diagnostic tools.

The innovation landscape is characterized by gradual improvements in kit sensitivity and specificity. However, the demand-supply balance may be impacted by fluctuations in research funding and regulatory approvals. Key risk factors include intense competition from alternative diagnostic technologies and potential supply chain disruptions. Overall, stakeholders must carefully navigate these factors to capitalize on emerging opportunities in the CD30 (TNFRSF8) ELISA Kit market.

12 items

1. Executive Summary

2. CD30 (TNFRSF8) ELISA Kit Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global CD30 (TNFRSF8) ELISA Kit Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global CD30 (TNFRSF8) ELISA Kit Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global CD30 (TNFRSF8) ELISA Kit Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global CD30 (TNFRSF8) ELISA Kit Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global CD30 (TNFRSF8) ELISA Kit Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global CD30 (TNFRSF8) ELISA Kit Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global CD30 (TNFRSF8) ELISA Kit Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global CD30 (TNFRSF8) ELISA Kit Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global CD30 (TNFRSF8) ELISA Kit Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global CD30 (TNFRSF8) ELISA Kit Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global CD30 (TNFRSF8) ELISA Kit Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global CD30 (TNFRSF8) ELISA Kit Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global CD30 (TNFRSF8) ELISA Kit Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global CD30 (TNFRSF8) ELISA Kit Market Competition by Key Manufacturers

9.1. Global CD30 (TNFRSF8) ELISA Kit Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global CD30 (TNFRSF8) ELISA Kit: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Sino Biological, Inc.

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Bio-Techne

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. MyBiosource, Inc.

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Boster Biological Technology

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Assay Genie

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Signalway Antibody LLC

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Abbexa

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. RayBiotech, Inc.

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. Thermo Fisher Scientific (China) Co., Ltd.

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. Wuhan Fine Biotech Co., Ltd.

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

10.11. Abcam

10.11.1. Company Basic Information and Sales Area

10.11.2. Main Business/Business Overview

10.11.3. Product Portfolio

10.11.4. Financial

10.11.5. Recent Industry Insights

10.11.6. SWOT Analysis

10.12. CUSABIO

10.12.1. Company Basic Information and Sales Area

10.12.2. Main Business/Business Overview

10.12.3. Product Portfolio

10.12.4. Financial

10.12.5. Recent Industry Insights

10.12.6. SWOT Analysis

10.13. Innovative Research

10.13.1. Company Basic Information and Sales Area

10.13.2. Main Business/Business Overview

10.13.3. Product Portfolio

10.13.4. Financial

10.13.5. Recent Industry Insights

10.13.6. SWOT Analysis

10.14. Geno Technology, Inc.

10.14.1. Company Basic Information and Sales Area

10.14.2. Main Business/Business Overview

10.14.3. Product Portfolio

10.14.4. Financial

10.14.5. Recent Industry Insights

10.14.6. SWOT Analysis

10.15. Arigo Biolaboratories Corp.

10.15.1. Company Basic Information and Sales Area

10.15.2. Main Business/Business Overview

10.15.3. Product Portfolio

10.15.4. Financial

10.15.5. Recent Industry Insights

10.15.6. SWOT Analysis

10.16. LifeSpan BioSciences, Inc

10.16.1. Company Basic Information and Sales Area

10.16.2. Main Business/Business Overview

10.16.3. Product Portfolio

10.16.4. Financial

10.16.5. Recent Industry Insights

10.16.6. SWOT Analysis

10.17. Biomatik

10.17.1. Company Basic Information and Sales Area

10.17.2. Main Business/Business Overview

10.17.3. Product Portfolio

10.17.4. Financial

10.17.5. Recent Industry Insights

10.17.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global CD30 (TNFRSF8) ELISA Kit Market

Figure 4: Global CD30 (TNFRSF8) ELISA Kit Market: Drivers

Figure 5: Global CD30 (TNFRSF8) ELISA Kit Market: Challenges

Figure 6: Global CD30 (TNFRSF8) ELISA Kit Market: Trends

Figure 7: Global CD30 (TNFRSF8) ELISA Kit Market: Opportunity

Figure 8: Global CD30 (TNFRSF8) ELISA Kit Market: Restraint

Figure 9: Global CD30 (TNFRSF8) ELISA Kit Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global CD30 (TNFRSF8) ELISA Kit Market Value (USD Million) By Region

Figure 19: Global CD30 (TNFRSF8) ELISA Kit Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global CD30 (TNFRSF8) ELISA Kit Market Value (USD Million) By Region

Figure 27: Global CD30 (TNFRSF8) ELISA Kit Market Share (%) By: Regions (2032)

Figure 28: Global CD30 (TNFRSF8) ELISA Kit Market Volume (K) By Region

Figure 29: Global CD30 (TNFRSF8) ELISA Kit Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global CD30 (TNFRSF8) ELISA Kit Market Value (USD Million) By Region

Figure 37: Global CD30 (TNFRSF8) ELISA Kit Market Share (%) By: Regions (2032)

Figure 38: Global CD30 (TNFRSF8) ELISA Kit Market Volume (K) By Region

Figure 39: Global CD30 (TNFRSF8) ELISA Kit Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

129 items

Table 1: Market Segmentation Analysis

Table 2: Global CD30 (TNFRSF8) ELISA Kit Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global CD30 (TNFRSF8) ELISA Kit Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global CD30 (TNFRSF8) ELISA Kit Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global CD30 (TNFRSF8) ELISA Kit Market Value (USD Million) By Region

Table 14: Global CD30 (TNFRSF8) ELISA Kit Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global CD30 (TNFRSF8) ELISA Kit Market Volume (K) By Region

Table 31: Global CD30 (TNFRSF8) ELISA Kit Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global CD30 (TNFRSF8) ELISA Kit Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global CD30 (TNFRSF8) ELISA Kit Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global CD30 (TNFRSF8) ELISA Kit Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Sino Biological, Inc. Basic Information And Sales Area

Table 52: Sino Biological, Inc.. Products Portfolio

Table 53: Bio-Techne Basic Information And Sales Area

Table 54: Bio-Techne. Products Portfolio

Table 55: MyBiosource, Inc. Basic Information And Sales Area

Table 56: MyBiosource, Inc.. Products Portfolio

Table 57: Boster Biological Technology Basic Information And Sales Area

Table 58: Boster Biological Technology. Products Portfolio

Table 59: Assay Genie Basic Information And Sales Area

Table 60: Assay Genie. Products Portfolio

Table 61: Signalway Antibody LLC Basic Information And Sales Area

Table 62: Signalway Antibody LLC. Products Portfolio

Table 63: Abbexa Basic Information And Sales Area

Table 64: Abbexa. Products Portfolio

Table 65: RayBiotech, Inc. Basic Information And Sales Area

Table 66: RayBiotech, Inc.. Products Portfolio

Table 67: Thermo Fisher Scientific (China) Co., Ltd. Basic Information And Sales Area

Table 68: Thermo Fisher Scientific (China) Co., Ltd.. Products Portfolio

Table 69: Wuhan Fine Biotech Co., Ltd. Basic Information And Sales Area

Table 70: Wuhan Fine Biotech Co., Ltd.. Products Portfolio

Table 71: Abcam Basic Information And Sales Area

Table 72: Abcam. Products Portfolio

Table 73: CUSABIO Basic Information And Sales Area

Table 74: CUSABIO. Products Portfolio

Table 75: Innovative Research Basic Information And Sales Area

Table 76: Innovative Research. Products Portfolio

Table 77: Geno Technology, Inc. Basic Information And Sales Area

Table 78: Geno Technology, Inc.. Products Portfolio

Table 79: Arigo Biolaboratories Corp. Basic Information And Sales Area

Table 80: Arigo Biolaboratories Corp.. Products Portfolio

Table 81: LifeSpan BioSciences, Inc Basic Information And Sales Area

Table 82: LifeSpan BioSciences, Inc. Products Portfolio

Table 83: Biomatik Basic Information And Sales Area

Table 84: Biomatik. Products Portfolio

Table 85: Global Market Value (USD Million) (2025-2032) By Application

Table 86: Global Market Share (%) By Application (2032)

Table 87: Global Market Value (USD Million) (2025-2032) By Types

Table 88: Global Market Share (%) By Types (2032)

Table 89: Global Market Volume (K) (2025-2032) By Application

Table 90: Global Market Share (%) By Application (2032)

Table 91: Global Market Volume (K) (2025-2032) By Types

Table 92: Global Market Share (%) By Types (2032)

Table 93: Global CD30 (TNFRSF8) ELISA Kit Market Value (USD Million) By Region

Table 94: Global CD30 (TNFRSF8) ELISA Kit Market Share (%) By Region (2025-2032)

Table 95: North America Market Value (USD Million) (2025-2032) By Country

Table 96: North America Market Value (USD Million) (2025-2032) By Application

Table 97: North America Market Value (USD Million) (2025-2032) By Types

Table 98: Europe Market Value (USD Million) (2025-2032) By Country

Table 99: Europe Market Value (USD Million) (2025-2032) By Application

Table 100: Europe Market Value (USD Million) (2025-2032) By Types

Table 101: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 102: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 103: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 104: South America Market Value (USD Million) (2025-2032) By Country

Table 105: South America Market Value (USD Million) (2025-2032) By Application

Table 106: South America Market Value (USD Million) (2025-2032) By Types

Table 107: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 108: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 109: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 110: Global CD30 (TNFRSF8) ELISA Kit Market Volume (K) By Region

Table 111: Global CD30 (TNFRSF8) ELISA Kit Market Share (%) By Region (2025-2032)

Table 112: North America Market Volume (K) (2025-2032) By Country

Table 113: North America Market Volume (K) (2025-2032) By Application

Table 114: North America Market Volume (K) (2025-2032) By Types

Table 115: Europe Market Volume (K) (2025-2032) By Country

Table 116: Europe Market Volume (K) (2025-2032) By Application

Table 117: Europe Market Volume (K) (2025-2032) By Types

Table 118: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 119: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 120: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 121: South America Market Volume (K) (2025-2032) By Country

Table 122: South America Market Volume (K) (2025-2032) By Application

Table 123: South America Market Volume (K) (2025-2032) By Types

Table 124: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 125: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 126: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 127: Research Programs/Design For This Report

Table 128: Key Data Information From Secondary Sources

Table 129: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

CD30 (TNFRSF8) ELISA Kit Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	450.00 million
Revenue forecast in 2033	784.82 million
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Sino Biological, Inc.; Bio-Techne; MyBiosource, Inc.; Boster Biological Technology; Assay Genie; Signalway Antibody LLC; Abbexa; RayBiotech, Inc.; Thermo Fisher Scientific (China) Co., Ltd.; Wuhan Fine Biotech Co., Ltd.; Abcam; CUSABIO; Innovative Research; Geno Technology, Inc.; Arigo Biolaboratories Corp.; LifeSpan BioSciences, Inc; Biomatik
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options